NCT00002369已完成不适用
An Open Label, Randomized, Comparative Study of Zerit (d4T) + Epivir (3TC) + Crixivan Versus Retrovir (AZT) + Epivir (3TC) + Crixivan in HIV-Infected, Antiretroviral Naive Subjects With CD4 Cell Counts of 200 - 700 Cells/mm3 and HIV RNA Baseline Copy Number of >= 10,000 Copies/ml
Bristol-Myers Squibb11 个研究点 分布在 2 个国家目标入组 200 人开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 200
- 试验地点
- 11
研究概览
简要总结
To evaluate the tolerance, and comparative virologic and immunologic effects of the two combination regimens.
详细描述
100 patients will be randomized to receive Zerit (Stavudine) + Epivir (Lamivudine) + Crixivan (Indinavir) and 100 patients will be randomized to receive Retrovir (Zidovudine) + Epivir (Lamivudine) + Crixivan (Indinavir).
Patients will be treated for 48 weeks.
研究设计
- 研究类型
- Interventional
- 干预模型
- Parallel
- 主要目的
- Treatment
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have:
- •Documented HIV infection.
- •CD4 cell count of 200 - 700 cells/mm3.
排除标准
- •Co-existing Condition:
- •Patients with the following symptoms or conditions are excluded:
- •AIDS defining condition within 1 month of study entry.
- •Prior Medication:
- •Patients with any history of antiretroviral therapy treatment.
研究者
研究点 (11)
Loading locations...
相似试验
已完成
不适用
A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected PatientsHIV InfectionsNCT00002168Bristol-Myers Squibb200
已完成
2 期
Tenofovir/Emtricitabine for PMTCT in Africa and Asia (ANRS 12109 TEmAA)HIV InfectionPregnancyNCT00334256French National Agency for Research on AIDS and Viral Hepatitis72
已完成
3 期
Study to Evaluate the Effectiveness of ABC+3TC +EFV in Once-Daily Regimens Versus KLT in Twice-Daily Regimens in Naive HIV PatientsHIV InfectionsNCT00318123Germans Trias i Pujol Hospital126
已完成
1 期
Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)Pneumococcal InfectionNCT04665050Merck Sharp & Dohme LLC102
已完成
1 期
Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB3 in Healthy Male SubjectsHealthyNCT02075073Samsung Bioepis Co., Ltd.109